Novo’s GLP-1s see another 1Q sales dip

For the second year in a row, Novo’s semaglutide franchise got off to a slow start. In 1Q25, sales of the pharma’s three GLP-1R agonist formulations — Ozempic, Wegovy and Rybelsus — declined quarter-over-quarter, as reported in DKK. However, Ozempic sales were up slightly in U.S. dollars (see Chart).

Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) lowered its 2025 sales growth projections by 3%, citing lower-than-expected U.S. market penetration due to competition from compounded GLP-1s. ...